Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5% [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
Expected to Reach USD 62.3 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ZIM Laboratories Limited, Sunovion Pharmaceuticals, Inc, C.L.Pharm Co., Ltd, IntelGenx Corp, CURE Pharmaceutical, Seoul Pharmaceuticals, Aquestive Therapeutics, Inc, Jazz Pharmaceuticals, plc, NAL Pharma, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, and other key vendors. New York, United States , May 16, 2024 (GLOBE NEWSWIRE) -- The Global Oral Transmucosal Drugs Market Size is to Grow from USD 33.2 Billion in 2023 to USD 62.3 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 6.5% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4011 Transdermal drug delivery devices, which transport medications through the skin for therapeutic purposes, are an effective alternative to oral intravascular, subcutaneous, and transmucosal routes. Transmucosal drug delivery ha
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual FilmGlobeNewswire
- Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years [Yahoo! Finance]Yahoo! Finance
AQST
Earnings
- 5/7/24 - Miss
AQST
Sec Filings
- 6/21/24 - Form 8-K
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- AQST's page on the SEC website